Matriptase
From Proteopedia
(Difference between revisions)
| Line 16: | Line 16: | ||
</StructureSection> | </StructureSection> | ||
| - | |||
| - | == 3D Structures of matriptase == | ||
| - | |||
| - | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| - | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | |||
| - | *'''matriptase''' | ||
| - | |||
| - | **[[4is5]], [[5lyo]] – hST14 catalytic domain - human<br /> | ||
| - | |||
| - | *Matriptase complex with small molecule inhibitor | ||
| - | |||
| - | **[[1eax]] – hST14 catalytic domain + benzamidine <br /> | ||
| - | **[[3p8g]] – hST14 residues 182-422 (mutant) + benzamidine <br /> | ||
| - | **[[2gv6]] – hST14 catalytic domain + benzamidine derivative<br /> | ||
| - | **[[4o97]], [[4o9v]] – hST14 catalytic domain + benzamidine derivative + tetrapeptide<br /> | ||
| - | **[[3ncl]] – hST14 catalytic domain (mutant) + benzamidine derivative<br /> | ||
| - | **[[2gv7]], [[4jz1]], [[4jzi]], [[4jyt]], [[4r0i]] – hST14 catalytic domain + inhibitor<br /> | ||
| - | **[[6n4t]] – hST14 catalytic domain + benzothiazole derivative<br /> | ||
| - | |||
| - | *Matriptase complex with polypeptide inhibitor | ||
| - | |||
| - | **[[1eaw]] – hST14 catalytic domain + BPTI<br /> | ||
| - | **[[3bn9]] – hST14 catalytic domain + antibody<br /> | ||
| - | **[[3nps]], [[3so3]] – hST14 catalytic domain (mutant) + antibody<br /> | ||
| - | **[[3p8f]] – hST14 residues 182-422 (mutant) + trypsin inhibitor peptide <br /> | ||
| - | **[[4isl]], [[4isn]], [[4iso]] – hST14 catalytic domain (mutant) + Kunitz-type protease inhibitor <br /> | ||
| - | }} | ||
== References == | == References == | ||
Current revision
| |||||||||||
References
- ↑ List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol Med. 2006 Jan-Mar;12(1-3):1-7. PMID:16838070 doi:http://dx.doi.org/10.2119/2006-00022.List
- ↑ Johnson MD, Oberst MD, Lin CY, Dickson RB. Possible role of matriptase in the diagnosis of ovarian cancer. Expert Rev Mol Diagn. 2003 May;3(3):331-8. PMID:12779007 doi:http://dx.doi.org/10.1586/14737159.3.3.331
- ↑ Chen CJ, Wu BY, Tsao PI, Chen CY, Wu MH, Chan YL, Lee HS, Johnson MD, Eckert RL, Chen YW, Chou F, Wang JK, Lin CY. Increased matriptase zymogen activation in inflammatory skin disorders. Am J Physiol Cell Physiol. 2011 Mar;300(3):C406-15. doi:, 10.1152/ajpcell.00403.2010. Epub 2010 Dec 1. PMID:21123732 doi:http://dx.doi.org/10.1152/ajpcell.00403.2010
- ↑ Friedrich R, Fuentes-Prior P, Ong E, Coombs G, Hunter M, Oehler R, Pierson D, Gonzalez R, Huber R, Bode W, Madison EL. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem. 2002 Jan 18;277(3):2160-8. Epub 2001 Nov 5. PMID:11696548 doi:10.1074/jbc.M109830200
